UOC
ANIP icon

UBS O'Connor’s ANI Pharmaceuticals ANIP Stock Holding History

UBS O'Connor’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-46,773
Closed -$2.64M – 725
2014
Q4 		$2.64M Buy
+46,773
New +$2.06M 0.05% 255

Other funds holding ANIP

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

UBS O'Connor's ANIP Position: Q1 2015 in Review

UBS O'Connor sold out of ANI Pharmaceuticals (ANIP) in Q1 2015, closing a stake of 46,773 shares — an estimated $2.64M sold.

UBS O'Connor first reported a position in ANIP in Q4 2014 and held it in 1 quarter. The position peaked at $2.64M in Q4 2014. 126 funds tracked by Wall St. Rank hold ANIP as of Q1 2015.

  • UBS O'Connor reported no remaining ANI Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • UBS O'Connor sold 46,773 ANI Pharmaceuticals shares in Q1 2015, an estimated $2.64M.
  • UBS O'Connor first reported a position in ANI Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • UBS O'Connor's ANI Pharmaceuticals position peaked at $2.64M in Q4 2014.
  • 126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2015.

Based on UBS O'Connor's 13F filing for Q1 2015, filed 14 May 2015.